How rising oil prices can boost the cost of some medicines
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Sales from controversial U.S. drug discount program rose to $100B last year
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Colorado’s first-of-its-kind price cap on an Amgen drug blocked
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Capricor Therapeutics accuses Nippon Shinyaku of slow-walking Duchenne drug
Capricor Therapeutics accused Nippon Shinyaku and its U.S. subsidiary of failing to follow through on marketing plans for…
How a 340B successor might arise from the drug price negotiations
The 340B drug discount program requires manufacturers to sell drugs to safety-net hospitals at deep discounts, so they…
Consumer group presses U.S. to authorize generic GLP-1s
Public Citizen petitioned the Trump administration to use a federal law to authorize generic competitors for GLP-1 drugs…
Johnson & Johnson, U.S. agree on drug discounts, new plants
Key Terms
tariffs
regulatory
Tariffs are taxes imposed by a government on goods…
STAT staffers share stories they wish they had written in 2025
This year saw upheaval in all corners of health, science, and biotech. While our staff was covering all…
Mark Cuban tries to shake up biosimilar pricing with a version of J&J’s Stelara
In its latest bid to shake up the prescription drug market, the Mark Cuban Cost Plus Drug Company…
Launch prices for new drugs ‘significantly’ exceed inflation, analysis says
Amid intensifying angst over prescription drug prices, a new analysis found that the median net price for 154…
Coverage of Sarepta Duchenne drug may be halted by N.Y. state Medicaid
In a setback for Sarepta Therapeutics, a New York panel has voted unanimously to recommend the state Medicaid…
Court rules against Novo Nordisk on Medicare price negotiations
A federal appeals court unanimously rejected a Novo Nordisk challenge to Medicare’s drug price negotiation program, a ruling…